CCC Project - Atrial Fibrillation

NCT02309398 | Completed

• 1 other identifier: CCC-AF-2014
• Study Type: observational
• Target: 67,028
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to develop and implement quality improvement programs for the treatment of atrial fibrillation (AF) in China based on the successful experience of the AHA-Get with the Guidelines program. This program will use data collection, analysis, feedback, and process improvement to extend the use of evidence-based guidelines throughout the healthcare system and improve patient care of atrial fibrillation.

Conditions

Atrial Fibrillation

Outcome Measures

Primary Outcomes (1)

• The overall composite of six performance measures for AF care

  Performance measures for AF care including: 1. Proportion of patients received assessment of thromboembolic risk factors 2. Proportion of patients discharged on warfarin or other anticoagulant drug 3. Proportion of patients discharged on warfarin who have PT/INR follow-up planned prior to hospital discharge 4. Proportion of patients with left ventricular systolic dysfunction prescribed an ACEI or ARB at hospital discharge 5. Proportion of patients with left ventricular systolic dysfunction prescribed a beta blocker at hospital discharge 6. Proportion of patients with either coronary artery disease, cerebrovascular accident/transient ischemic attack, peripheral vascular disease or diabetes who were prescribed a statin at hospital discharge

  Duration of hospital stay, an expected average of 1 week

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Hospitalized patients of atrial fibrillation

You may qualify if:

• Hospitalized patients with discharge diagnosis as atrial fibrillation in 150 tertiary and 100 secondary hospitals.

You may not qualify if:

• None

Sponsors & Collaborators

• Beijing Institute of Heart, Lung and Blood Vessel Diseases: lead
• American Heart Association: collaborator
• Chinese Society of Cardiology: collaborator

Study Sites (1)

Beijing An Zhen Hospital

Beijing, China

Location

Related Publications (7)

• Hao Y, Liu J, Smith SC, Huo Y, Fonarow GC, Ge J, Liu J, Taubert KA, Morgan L, Guo Y, Zhou M, Zhao D, Ma C; CCC-AF Investigators. Rationale and design of the improving Care for Cardiovascular Disease in China (CCC) project: a national registry to improve management of atrial fibrillation. BMJ Open. 2018 Jul 5;8(7):e020968. doi: 10.1136/bmjopen-2017-020968.

  PMID: 29980544 RESULT

• Han K, Li X, Fu B, Li M, Liu T, Peng Y, Liu J, Yang N, Hao Y, Jiang C, Tang R, Dong J, Zhao D, Long D, Ma C. Elevated Resting Heart Rate in Hospitalized Patients With Atrial Fibrillation Is Associated With Increased Cardiovascular Risk. Cardiovasc Ther. 2026 Jan 26;2026:2106637. doi: 10.1155/cdr/2106637. eCollection 2026.

  PMID: 41608332 DERIVED

• Tong XY, Lin J, Sun ZQ, He Q, Zhan Y, Jiang CX, Tang RB, Sang CH, Ning M, Jia CQ, Feng L, Wang W, Zhao X, Li CY, Li SN, Guo XY, Liu T, Li MM, Yang N, Hao YC, Liu J, Liu J, Xie J, Long DY, Dong JZ, Zhao D, Ma CS. Low-density lipoprotein cholesterol levels and in-hospital bleeding in patients with atrial fibrillation: findings from CCC-AF project. Front Cardiovasc Med. 2025 Jun 12;12:1574796. doi: 10.3389/fcvm.2025.1574796. eCollection 2025.

  PMID: 40574812 DERIVED

• Yang N, Sun Z, Liu J, Hao Y, Long D, Zhao D, Liu J; CCC-AF Investigators. Impact of insurance coverage for non-vitamin K antagonist oral anticoagulants on quality of care and care disparities in patients hospitalised with atrial fibrillation in tertiary hospitals in China: interrupted time series analysis. BMJ Open. 2025 Feb 22;15(2):e088539. doi: 10.1136/bmjopen-2024-088539.

  PMID: 39986999 DERIVED

• Xia Y, Jiang J, Fan F, Pan Y, Zhou J, Zhang Y, Li J, Liu J, Yang N, Hao Y, Zhao D, Liu J, Ma C, Huo Y; CCC-AF investigators. Prevalence, Characteristics, and Treatment Strategy of Different Types of Heart Failure in Patients With Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2024 Oct;13(19):e033941. doi: 10.1161/JAHA.123.033941. Epub 2024 Sep 30.

  PMID: 39344652 DERIVED

• Lin J, Long D, Jiang C, Sang C, Tang R, Li S, Wang W, Guo X, Ning M, Sun Z, Yang N, Hao Y, Liu J, Liu J, Du X, Morgan L, Fonarow GC, Smith SC Jr, Lip GYH, Zhao D, Dong J, Ma C; CCC-AF investigators. Oral anti-coagulants use in Chinese hospitalized patients with atrial fibrillation. Chin Med J (Engl). 2024 Jan 20;137(2):172-180. doi: 10.1097/CM9.0000000000002915. Epub 2023 Dec 22.

  PMID: 38146256 DERIVED

• He P, Pan Y, Jiang J, Fan F, Zhou J, Xia Y, Liu J, Yang N, Hao Y, Li J, Liu J, Zhao D, Huo Y; CCC-AF investigators. In-hospital therapies and determinants of treatment strategy selection in patients with atrial fibrillation and left ventricular systolic dysfunction in China: a retrospective study based on the Improving Care for Cardiovascular Disease in China-Atrial Fibrillation (CCC-AF) project, 2015-2019. BMJ Open. 2023 Jun 5;13(6):e070070. doi: 10.1136/bmjopen-2022-070070.

  PMID: 37277219 DERIVED

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Dong Zhao, Ph. D

  Beijing Institute of Heart, Lung and Blood Vessel Diseases

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: November 30, 2014
• First Posted: December 5, 2014
• Study Start: January 1, 2015
• Primary Completion: December 1, 2020
• Study Completion: December 1, 2020
• Last Updated: January 27, 2021

Record last verified: 2021-01

Locations

CN (1)